China gives conditional approval for Pfizer’s COVID drug Paxlovid

BEIJING (Reuters) – China’s medical products regulator said on Saturday it has given conditional approval for Pfizer (NYSE:)’s COVID-19 medicine Paxlovid to treat adults with mild to moderate disease who have high risk of progressing to a severe condition.

The National Medical Products Administration said further study on the drug needed to be conducted and submitted to the authority.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.